N-aryl pyrazoles, indazoles and azaindazoles as antagonists of CC chemokine receptor 1: patent cooperation treaty applications WO2010/036632, WO2009/134666 and WO2009/137338

Bibliography

• Gaga M, Ong YE, Benyahia F, Skin reactivity and local cell recruitment in human atopic and nonatopic subjects by CCL2/MCP-1 and CCL3/MIP-1alpha. Allergy 2008;63:703-11
   PubMedGoogle Scholar
• Lee SC, Brummet ME, Shahabuddin S, Cutaneous injection of human subjects with macrophage inflammatory protein-1 alpha induces significant recruitment of neutrophils and monocytes. J Immunol 2000;164:3392-401
   PubMed Web of Science ®Google Scholar
• Allen SJ, Crown SE, Handel TM. Chemokine:receptor structure, interactions, and antagonism. Annu Rev Immunol 2007;25:787-820
   PubMed Web of Science ®Google Scholar
• Sallusto F, Baggiolini M. Chemokines and leukocyte traffic. Nat Immunol 2008;9:949-52
   PubMed Web of Science ®Google Scholar
• Viola A, Luster AD. Chemokines and their receptors: drug targets in immunity and inflammation. Annu Rev Pharmacol Toxicol 2008;48:171-97
   PubMed Web of Science ®Google Scholar
• Horuk R. Chemokine receptor antagonists: overcoming developmental hurdles. Nat Rev Drug Discov 2009;8:23-33
   PubMed Web of Science ®Google Scholar
• Carson KG, Jaffee BD, Harriman GCB. CCR1 antagonists. Annu Rep Med Chem 2004;39:149-58
   Google Scholar
• Pease JE, Horuk R. CCR1 antagonists in clinical development. Expert Opin Investig Drugs 2005;14:785-96
   PubMed Web of Science ®Google Scholar
• Carter PH. Chemokine receptor antagonism as an approach to anti-inflammatory therapy: ‘just right’ or plain wrong? Curr Opin Chem Biol 2002;6:510-25
   PubMed Web of Science ®Google Scholar
• Gao Z, Metz WA. Unraveling the chemistry of chemokine receptor ligands. Chem Rev 2003;103:3733-52
   PubMed Web of Science ®Google Scholar
• Schwarz MK, Wells TN. New therapeutics that modulate chemokine networks. Nat Rev Drug Discov 2002;1:347-58
   PubMed Web of Science ®Google Scholar
• Pease JE, Horuk R. Chemokine receptor antagonists: Part 1. Expert Opin Ther Pat 2009;19:39-58
   PubMed Web of Science ®Google Scholar
• Pease JE, Horuk R. Chemokine receptor antagonists: Part 2. Expert Opin Ther Pat 2009;19:199-221
   PubMed Web of Science ®Google Scholar
• Zipp F, Hartung HP, Hillert J, CCR1 Antagonist Study Group. Blockade of chemokine signaling in patients with multiple sclerosis. Neurology 2006;67:1880-3
   PubMed Web of Science ®Google Scholar
• Kerstjens HA, Bjermer L, Eriksson L, Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients. Respir Med 2010;104:1297-303
   PubMedGoogle Scholar
• Norman P. AZD-4818, a chemokine CCR1 antagonist: WO2008103126 and WO2009011653. Expert Opin Ther Pat 2009;19:1629-33
   PubMed Web of Science ®Google Scholar
• Haringman JJ, Kraan MC, Smeets TJ, Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:715-21
   PubMed Web of Science ®Google Scholar
• Borregaard J, Skov L, Wang L, Evaluation of the effect of the specific CCR1 antagonist CP-481715 on the clinical and cellular responses observed following epicutaneous nickel challenge in human subjects. Contact Dermatitis 2008;59:212-19
   PubMedGoogle Scholar
• Lu C, Balani SK, Qian MG, Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonist. J Pharmacol Exp Ther 2010;332:562-8
   PubMedGoogle Scholar
• Vergunst CE, Gerlag DM, von Moltke L, MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study. Arthritis Rheum 2009;60:3572-81
   PubMed Web of Science ®Google Scholar
• Chemocentryx, Inc. Preparation of pyrazolopyridylacetylpiperazinylbenzenes as CCR1 chemokine receptor antagonists. WO2008147822; 2008
   Google Scholar
• Chemocentryx, Inc. Preparation of 3-imidazolylpyrazolo[3,4-b]pyridines as chemokine binding inhibitors. WO2008147815; 2008
   Google Scholar
• Chemocentryx, Inc. Preparation of 4-amino-3-(imidazolyl)pyrazolo[3,4-d]pyrimidines as CCR1 chemokine receptor antagonists. WO2010030815; 2010
   Google Scholar
• Boehringer Ingelheim International GMBH. Pyrazole compounds as CCR1 antagonists. WO2009137338; 2009
   Google Scholar
• Boehringer Ingelheim International GMBH. Indazole compounds as CCR1 antagonists. WO2009134666; 2009
   Google Scholar
• Boehringer Ingelheim International GMBH. Azaindazole compounds as CCR1 antagonists. WO2010036632; 2010
   Google Scholar
• Tanuwidjaja J, Peltier HM, Ellman JA. One-pot asymmetric synthesis of either diastereomer of tert-butanesulfinyl-protected amines from ketones. J Org Chem 2007;72:626-9, and references cited therein
   PubMedGoogle Scholar
• Vistoli G, Pedretti A, Testa B. Assessing drug-likeness – what are we missing? Drug Discov Today 2008;13:285-94
   PubMed Web of Science ®Google Scholar
• Kromdijk W, Huitema AD, Mulder JW. Treatment of HIV infection with the CCR5 antagonist maraviroc. Expert Opin Pharmacother 2010;11:1215-23
   PubMed Web of Science ®Google Scholar
• Cashen AF. Plerixafor hydrochloride: a novel agent for the mobilization of peripheral blood stem cells. Drugs Today (Barc) 2009;45:497-505
   PubMed Web of Science ®Google Scholar
• Eksteen B, Adams DH. GSK-1605786, a selective small-molecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn's disease. IDrugs 2010;13:472-81
   PubMed Web of Science ®Google Scholar
• Carter PH, Zhao Q. Clinically validated approaches to the treatment of autoimmune diseases. Expert Opin Investig Drugs 2010;19:195-213
   PubMed Web of Science ®Google Scholar
• Isaacs JD. The changing face of rheumatoid arthritis: sustained remission for all? Nat Rev Immunol 2010;10:605-11
   PubMed Web of Science ®Google Scholar
• Vergunst CE, Gerlag DM, Lopatinskaya L, Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2008;58:1931-9
   PubMed Web of Science ®Google Scholar
• Gerlag DM, Hollis S, Layton M, Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate. Arthritis Rheum 2010. [Epub ahead of print]
   Google Scholar
• van Kuijk AW, Vergunst CE, Gerlag DM, CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis 2010. [Epub ahead of print]
   Google Scholar